Anxiety Disorders Completed Phase 3 Trials for Memantine (DB01043)

Also known as: Anxiety Disorder / Anxiety NOS

IndicationStatusPhase
DBCOND0027904 (Anxiety Disorders)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00674219Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety DisorderTreatment